135 related articles for article (PubMed ID: 12395079)
1. The Arctic mutation interferes with processing of the amyloid precursor protein.
Stenh C; Nilsberth C; Hammarbäck J; Engvall B; Näslund J; Lannfelt L
Neuroreport; 2002 Oct; 13(15):1857-60. PubMed ID: 12395079
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of familial Alzheimer's disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity.
Schilling S; Pradhan A; Heesch A; Helbig A; Blennow K; Koch C; Bertgen L; Koo EH; Brinkmalm G; Zetterberg H; Kins S; Eggert S
Acta Neuropathol Commun; 2023 Jun; 11(1):87. PubMed ID: 37259128
[TBL] [Abstract][Full Text] [Related]
3. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation.
Tsubuki S; Takaki Y; Saido TC
Lancet; 2003 Jun; 361(9373):1957-8. PubMed ID: 12801742
[TBL] [Abstract][Full Text] [Related]
4. Calpain inhibitor I increases beta-amyloid peptide production by inhibiting the degradation of the substrate of gamma-secretase. Evidence that substrate availability limits beta-amyloid peptide production.
Zhang L; Song L; Parker EM
J Biol Chem; 1999 Mar; 274(13):8966-72. PubMed ID: 10085142
[TBL] [Abstract][Full Text] [Related]
5. The X11alpha protein slows cellular amyloid precursor protein processing and reduces Abeta40 and Abeta42 secretion.
Borg JP; Yang Y; De Taddéo-Borg M; Margolis B; Turner RS
J Biol Chem; 1998 Jun; 273(24):14761-6. PubMed ID: 9614075
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease.
Liu CG; Wang JL; Li L; Wang PC
Int J Mol Med; 2014 Jul; 34(1):160-6. PubMed ID: 24827165
[TBL] [Abstract][Full Text] [Related]
7. Peripheral treatment with enoxaparin exacerbates amyloid plaque pathology in Tg2576 mice.
Cui H; King AE; Jacobson GA; Small DH
J Neurosci Res; 2017 Apr; 95(4):992-999. PubMed ID: 27546887
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
9. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid.
Bodendorf U; Danner S; Fischer F; Stefani M; Sturchler-Pierrat C; Wiederhold KH; Staufenbiel M; Paganetti P
J Neurochem; 2002 Mar; 80(5):799-806. PubMed ID: 11948243
[TBL] [Abstract][Full Text] [Related]
10. Chinese Presenilin-1 V97L mutation enhanced Abeta42 levels in SH-SY5Y neuroblastoma cells.
Fang B; Jia L; Jia J
Neurosci Lett; 2006 Oct; 406(1-2):33-7. PubMed ID: 16916581
[TBL] [Abstract][Full Text] [Related]
11. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence.
Reaume AG; Howland DS; Trusko SP; Savage MJ; Lang DM; Greenberg BD; Siman R; Scott RW
J Biol Chem; 1996 Sep; 271(38):23380-8. PubMed ID: 8798542
[TBL] [Abstract][Full Text] [Related]
12. BACE (beta-secretase) modulates the processing of APLP2 in vivo.
Pastorino L; Ikin AF; Lamprianou S; Vacaresse N; Revelli JP; Platt K; Paganetti P; Mathews PM; Harroch S; Buxbaum JD
Mol Cell Neurosci; 2004 Apr; 25(4):642-9. PubMed ID: 15080893
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability.
De Jonghe C; Esselens C; Kumar-Singh S; Craessaerts K; Serneels S; Checler F; Annaert W; Van Broeckhoven C; De Strooper B
Hum Mol Genet; 2001 Aug; 10(16):1665-71. PubMed ID: 11487570
[TBL] [Abstract][Full Text] [Related]
14. Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin.
Betts V; Leissring MA; Dolios G; Wang R; Selkoe DJ; Walsh DM
Neurobiol Dis; 2008 Sep; 31(3):442-50. PubMed ID: 18602473
[TBL] [Abstract][Full Text] [Related]
15. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
16. The amyloid beta protein precursor mutations linked to familial Alzheimer's disease alter processing in a way that fosters amyloid deposition.
Younkin SG
Tohoku J Exp Med; 1994 Nov; 174(3):217-23. PubMed ID: 7761987
[TBL] [Abstract][Full Text] [Related]
17. Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1.
Shimojo M; Sahara N; Murayama M; Ichinose H; Takashima A
Neurosci Res; 2007 Mar; 57(3):446-53. PubMed ID: 17210196
[TBL] [Abstract][Full Text] [Related]
18. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
[TBL] [Abstract][Full Text] [Related]
19. BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein.
Farzan M; Schnitzler CE; Vasilieva N; Leung D; Choe H
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9712-7. PubMed ID: 10931940
[TBL] [Abstract][Full Text] [Related]
20. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
